Efficacy of Cystic Fibrosis Transmembrane Regulator Corrector C17 in Beta-Sarcoglycanopathy—Assessment of Patient’s Primary Myotubes
Martina Scano, Alberto Benetollo, Francesco Dalla Barba, Eylem Emek Akyurek, Marcello Carotti, Roberta Sacchetto, Dorianna Sandonà, Daniel Taillandier · 2024
Read Efficacy of Cystic Fibrosis Transmembrane Regulator Corrector C17 in Beta-Sarcoglycanopathy—Assessment of Patient’s Primary Myotubes by Martina Scano, Alberto Benetollo, Francesco Dalla Barba, Eylem Emek Akyurek, Marcello Carotti, Roberta Sacchetto, Dorianna Sandonà, Daniel Taillandier (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11676211.txt.
Description
Scano and co-authors published a 2024 study testing a cystic fibrosis drug as a rescue for a rare muscle disease. In beta-sarcoglycanopathy, mutant proteins of the muscle membrane complex are marked for destruction, weakening the membrane. The team first confirmed in lab cells that mutant beta-sarcoglycan is degraded by the cell's proteasome, like its alpha sibling. They then worked in muscle cells grown from a patient.
A CFTR corrector called C17 saved the mutant protein from destruction and restored the full complex at the cell surface. Membrane integrity improved, judged by lower enzyme leakage under stress. The authors propose repurposing correctors, built for cystic fibrosis, for sarcoglycan diseases. The patient-cell evidence is the study's core strength.
Catalog record
| CREATOR | Martina Scano, Alberto Benetollo, Francesco Dalla Barba, Eylem Emek Akyurek, Marcello Carotti, Roberta Sacchetto, Dorianna Sandonà, Daniel Taillandier |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 43 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |